Water for Injection Market Report 2025

The water for injection market size has grown strongly in recent years. It will grow from $27.79 billion in 2024 to $30.45 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth during the historic period can be attributed to increasing demand for parenteral drugs, stricter enforcement of GMP standards worldwide, growth in biologics production, a rise in contract manufacturing activities, expansion of hospital-based manufacturing, and increased adoption of aseptic packaging.

The water for injection market size is expected to see strong growth in the next few years. It will grow to $43.6 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The anticipated growth in the forecast period can be attributed to increasing regulatory approvals for non-distillation production methods, expansion of biopharmaceutical manufacturing in emerging markets, growing demand for fast-deployable plug-and-play water systems, rising need from advanced therapy medicinal products, and the surge in personalized medicine. Key trends during this period include innovations in decentralized water generation systems, the use of IoT-enabled water for injection technologies, application of AI and machine learning in water generation processes, combined approaches utilizing vapor compression distillation, and the adoption of cutting-edge technologies.

The rising prevalence of diabetes is expected to drive the growth of the water for injection market in the coming years. Diabetes is a chronic condition where the body cannot properly regulate blood sugar (glucose) levels, either due to inadequate insulin production or ineffective insulin use. This increase in diabetes cases is largely linked to the global rise in obesity, as excess body fat impairs the body’s ability to use insulin effectively, leading to poor blood sugar control and a higher risk of developing the disease. Water for injection is frequently used in diabetes care to reconstitute or dilute injectable medications like insulin, ensuring these drugs are administered safely and sterility is maintained to preserve their effectiveness and prevent infections. For example, in February 2025, the Health Professional Academy, a UK-based personalized health professional learning platform, reported that the number of people diagnosed with diabetes in the UK reached a record 4.6 million, up from 4.4 million the previous year. Consequently, the growing prevalence of diabetes is supporting the expansion of the water for injection market.

Leading companies in the water for injection market are developing advanced technologies, such as cold water for injection systems, to lower energy consumption and operational costs while meeting regulatory requirements. Cold water for injection technology involves producing water for injection using membrane-based purification at ambient temperatures, removing the need for traditional distillation but still complying with pharmacopeial standards. For instance, in December 2024, CN Water Systems Pvt. Ltd., an India-based pharmaceutical firm, launched its OSMOTRON Cold/Ambient Water for Injection (WFI) technology, which substantially cuts energy use and operational expenses compared to conventional distillation. This system produces WFI directly from potable water without requiring water softening or dechlorination, employing a triple-membrane barrier to enhance safety and efficiency.

In March 2023, Milla Pharmaceuticals Inc., a US-based developer and marketer of generic prescription drugs, partnered with Athenex Pharmaceutical Division LLC to introduce a generic magnesium sulfate product in water for injection. This collaboration focuses on developing and launching a high-quality, cost-effective generic magnesium sulfate in water for injection, packaged in non-PVC, single-patient-use containers. This approach aims to improve patient safety, minimize contamination risks, and enhance accessibility of this critical medication to healthcare providers and patients worldwide. Athenex Pharmaceutical Division LLC is a US-based specialty oncology pharmaceutical company that produces generic magnesium sulfate in water for injection.

Major players in the water for injection market are Pfizer Inc., Veolia Water Technologies Inc., Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Eli Lilly and Co., Boehringer Ingelheim, Amgen Inc., Merck KGaA, Fresenius SE and Co. KGaA, Asahi Kasei Medical Co. Ltd., Sandoz International GmbH, Baxter International Inc., B. Braun Melsungen AG, Lonza Group AG, Apotex Inc., BWT AG, Sartorius AG, Wuxi Biologics Cayman Inc., ICU Medical Inc., Evoqua Water Technologies, and Cambrex Corporation.

North America was the largest region in the water for injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in water for injection report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the water for injection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The water for injection market consists of sales of injectable drugs, irrigation solutions, infusion fluids, ophthalmic solutions, inhalation solutions, and wound care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The water for injection market research report is one of a series of new reports that provides water for injection market statistics, including water for injection industry global market size, regional shares, competitors with a water for injection market share, detailed water for injection market segments, market trends and opportunities, and any further data you may need to thrive in the water for injection industry. This water for injection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Water for injection is sterile, highly purified water specifically designed for preparing parenteral (injectable) medications, where contaminants - including pyrogens - must be strictly eliminated. It is commonly produced through methods like distillation or reverse osmosis and must meet rigorous pharmaceutical quality standards to ensure safety for intravenous use.

The primary categories of water for injection include single-distilled water for injection, double-distilled water for injection, sterile water for injection, and purified water for injection. Single-distilled water for injection is produced by distilling water once to remove impurities and microorganisms. It is available in various packaging options, such as vials, ampules, bottles, drums, and bulk containers, and is manufactured using processes like distillation and membrane-based reverse osmosis. This type of water for injection is used in multiple applications, including as solvents and diluents, in culture media, for equipment cleaning, and more, serving a range of end users such as pharmaceutical and biotechnology firms, hospitals and healthcare facilities, contract research and manufacturing organizations, among others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.